Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design

Jonathan W. Riess, Paul Frankel, David Shackelford, Mark Dunphy, Ramsey D. Badawi, Lorenzo Nardo, Simon R. Cherry, Ian Lanza, Joel Reid, Wilson I. Gonsalves, Charles Kunos, David R. Gandara, Primo N. Lara, Edward Newman, Paul K. Paik

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design'. Together they form a unique fingerprint.

Medicine & Life Sciences